Skip to main content
. 2021 Feb 27;72(2):332–339. doi: 10.1007/s12020-021-02650-z

Table 3.

Main drug interactions between each anti-COVID-19 drug and each multikinase inhibitors (MKIs)

graphic file with name 12020_2021_2650_Tab1_HTML.jpg

aFavipiravir was not present in the online database and its QT-prolonging effect was documented by ref. [19]